Teva's senior notes and debentures and convertible debentures are issued by various special-purpose finance subsidiaries. All such debt is guaranteed by Teva Pharmaceutical Industries Ltd.
Quarterly Debt Factsheet
Senior Notes and Debentures
Issued |
Currency |
Annual Interest
(%) |
Principal Amount Issued
(U.S. $ in MM) |
Current Outstanding |
Due |
Prospectuses |
| January 2006 |
USD |
6.150 |
1,000 |
782 |
January 2036 |
|
| November 2011 |
USD |
3.650 |
1,750 |
1,208 |
November 2021 |
|
| April 2012 |
CHF |
1.500 |
459 |
0 |
October 2018 |
|
| December 2012 |
USD |
2.250 |
700 |
860 |
March 2020 |
|
| December 2012 |
USD |
2.950 |
1,300 |
862 |
December 2022 |
|
| March 2015 |
Euro |
1.250 |
1,480 |
1,501 |
March 2023 |
|
| March 2015 |
Euro |
1.875 |
789 |
810 |
March 2027 |
|
| July 2016 |
USD |
1.700 |
2,000 |
1,985 |
July 2019 |
|
| July 2016 |
USD |
2.200 |
3,000 |
2,997 |
July 2021 |
|
| July 2016 |
USD |
2.800 |
3,000 |
2,993 |
July 2023 |
|
| July 2016 |
USD |
3.150 |
3,500 |
3,493 |
October 2026 |
|
| July 2016 |
USD |
4.100 |
2,000 |
1,984 |
October 2046 |
|
| July 2016 |
CHF |
0.500 |
357 |
356 |
July 2022 |
|
| July 2016 |
CHF |
1.000 |
357 |
356 |
July 2025 |
|
| July 2016 |
Euro |
0.375 |
1,947 |
1,896 |
July 2020 |
|
| July 2016 |
Euro |
1.125 |
1,669 |
1,706 |
October 2024 |
|
| July 2016 |
Euro |
1.625 |
834 |
850 |
October 2028 |
|
| March 2018 |
USD |
6.000 |
1,250 |
1,250 |
April 2024 |
|
| March 2018 |
USD |
6.750 |
1,250 |
1,250 |
March 2028 |
|
| March 2018 |
Euro |
3.250 |
867 |
801 |
April 2022 |
|
| March 2018 |
Euro |
4.500 |
1,115 |
1,029 |
March 2025 |
|
Convertible Senior Debentures
| Issued |
Annual interest rate |
Initial Principal amount |
Principal amount at 3/31/2017 |
Year due |
Conversion price August 2018 |
No of Teva shares issuable upon full conversion at 3/31/2017 |
Earliest date of redemption at issuer's option / repurchase at holder's option |
| |
(%) |
(U.S. $ in MM) |
|
(U.S. $) |
(in MM) |
|
| January 2006(1) |
0.25 |
$575 |
$514 |
2026 |
$39.7841 |
See footnote 1 |
Issuer - on demand
Holders - on 2/1/2021 |
To view the prospectus supplement relating to the January 2006 debentures - click here
For conversion and other notices - click here
(1) These convertible senior debentures due 2026 include a "net share settlement" feature according to which the principal of the debentures will be paid in cash and in the case of conversion, only the residual conversion value above the principal will be paid in Teva shares.
Term Loans and Other Facilities
| Source |
Year
of
Facility |
Currency |
Annual
Interest Rate (%) |
Principal Amount
Issued |
Due |
Additional Information |
| |
|
|
(%) |
(U.S. $ in MM) |
|
|
Revolving Credit Facility* |
2015 |
USD |
USD Libor +1.875 |
- |
N/A |
$3.0 b facility available for 5 years |
*The following amendments document apply to the term loans and revolving credit facility noted above
Covenant Amendments – February 2018
Covenant Amendments – September 2017